Dupilumab reduces flare-ups in children with uncontrolled moderate-to-severe asthma, finds study

摘要

Adding the monoclonal antibody dupilumab to standard treatment could reduce exacerbations in children with uncontrolled moderate-to-severe asthma by almost 60, a randomised controlled trial has found. The Liberty Asthma VOYAGE trial, published in the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2106567) on 9 December 2021, assessed the annual rate of severe asthma exacerbations in 408 children with moderate-to-severe asthma aged 6–11 years over a period of 52 weeks.